American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
STAMFORD, Conn., Oct. 16, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at Kidney Week 2017, the American Society of Nephrology's Annual Meeting, to be held October 31 – November 5, 2017 in New Orleans, LA.
Presentations will include clinical data from a recently completed Phase 2b trial of I.V. CR845 in hemodialysis patients suffering from moderate-to-severe pruritus.
Details for the presentations are as follows:
CR845 Oral Presentation:
| Title: | "Randomized, Placebo-Controlled Study on the Efficacy of CR845 in Improving the Quality of Life of Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus” |
| Abstract Number: | SA-OR032 |
| Date / Time: | Saturday, November 4, 2017; 4:42 – 4:54 p.m. CT |
| Presenter: | Frédérique Menzaghi, Ph.D., Senior Vice President, Research and Development, Cara Therapeutics |
CR845 Poster Presentation:
| Poster Title: | "Randomized, Placebo-Controlled Study on the Efficacy of CR845 in Reducing Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients" |
| Poster Number: | FR-PO875 |
| Date / Time: | Friday, November 3, 2017; 9:30 a.m. – 2:30 p.m. CT |
| Presenter: | Robert Spencer, Ph.D., Senior Director, Research and Development, Cara Therapeutics |
Satellite Symposium:
| Title: | "Pioneering a Novel Approach to Relieve CKD-Associated Pruritus: Targeting Peripheral Kappa Opioid Receptors” |
| Date / Time: | Thursday, November 2, 2017; 10:00 – 11:00 a.m. CT |
| Moderator: | Joseph Stauffer, D.O., M.B.A., Chief Medical Officer, Cara Therapeutics |
| Faculty: | James A. Tumlin, M.D., F.A.S.N., Director & Chief Medical Officer, NephroNet, Clinical Trials Consortium; Founder & Medical Director, Southeast Renal Research Institute; Professor, Division of Nephrology, University of Tennessee College of Medicine |
For more information about Kidney Week 2017, visit https://www.asn-online.org/education/kidneyweek/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics.
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
[email protected]
